Federal contract opportunity SPE2D2-15-R-0009 for pharmaceutical preparation manufacturing at DLA Acquisition Locations Office: DLA Acquisition Locations.

Not available
Solicitation Number
Contract Number(s)
Additional Info Link
None listed
No Set-Aside Used

The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Bupropion XL. Procurement details follow.

Bupropion XL: 150MG and 300MG in 30, 90, and 500 (or 1000) count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Bureau of Prisons, Indian Health Service and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and FEDBIZOPS at https://www.fbo.gov. Interested parties should contact Danielle Delaney (215-737-2998) (danielle.delaney@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of presolicitation or solicitation changes through this website. The current projected solicitation date is June of 2015. DLA reserves the right to issue the solicitation before or after the projected solicitation date.


Package File Description
Award Final_PDF_award_Bupropion_XL.pdf SPE2D2-15-D-0025 Bupropion XL Award
Solicitation 2 update_Bupropion_XL_solicitation.docx SPE2D2-15-R-0009 Solicitation (Word Document)
Solicitation 1 pdf_update_Bupropion_XL_solicitation.pdf SPE2D2-15-R-0009 PDF Solicitation